Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus. / Hansen, Suzanne L; Nielsen, Ane H; Knudsen, Katrine E; Artmann, Andreas; Kristiansen, Uffe; Hansen, Steen Honore'; Hansen, Harald S; Petersen, Gitte.
I: Neurochemistry International, Bind 54, Nr. 3-4, 2009, s. 199-204.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus
AU - Hansen, Suzanne L
AU - Nielsen, Ane H
AU - Knudsen, Katrine E
AU - Artmann, Andreas
AU - Kristiansen, Uffe
AU - Hansen, Steen Honore'
AU - Hansen, Harald S
AU - Petersen, Gitte
N1 - Keywords: Animals; Convulsants; Disease Models, Animal; Down-Regulation; Endocannabinoids; Epilepsy; Ethanolamines; Hippocampus; Ketogenic Diet; Kindling, Neurologic; Male; Mice; Oleic Acids; Pentylenetetrazole; Receptor, Cannabinoid, CB1
PY - 2009
Y1 - 2009
N2 - The ketogenic diet (KD) is used for the treatment of refractory epilepsy in children, however, the mechanism(s) remains largely unknown. Also, the antiepileptogenic potential in animal models of epilepsy has been poorly addressed. Activation of cannabinoid type-1 receptor (CB(1)-R) upon seizure activity may mediate neuroprotection as may several N-acylethanolamines. It is unknown how the KD interfere with the endocannabinoid system. We investigated the antiepileptogenic potential of the KD in the pentylenetetrazole kindling model in young mice and measured the hippocampal levels of CB(1)-R by Western blot and of endocannabinoids and N-acylethanolamines by mass spectrometry. The KD significantly decreased incidence and severity of seizures, and significantly increased the latency to clonic convulsions. There were no changes in levels of endocannabinoids or CB(1)-R expression by either seizure activity or type of diet. The level of oleoylethanolamide as well as the sum of N-acylethanolamines were significantly decreased by the KD, but were unaffected by seizure activity. The study shows that the KD had clear antiepileptogenic properties in the pentylenetetrazole kindling model and does not support a role of endocannabinoids in this model. The significance of the decreased hippocampal level of oleoylethanolamide awaits further studies.
AB - The ketogenic diet (KD) is used for the treatment of refractory epilepsy in children, however, the mechanism(s) remains largely unknown. Also, the antiepileptogenic potential in animal models of epilepsy has been poorly addressed. Activation of cannabinoid type-1 receptor (CB(1)-R) upon seizure activity may mediate neuroprotection as may several N-acylethanolamines. It is unknown how the KD interfere with the endocannabinoid system. We investigated the antiepileptogenic potential of the KD in the pentylenetetrazole kindling model in young mice and measured the hippocampal levels of CB(1)-R by Western blot and of endocannabinoids and N-acylethanolamines by mass spectrometry. The KD significantly decreased incidence and severity of seizures, and significantly increased the latency to clonic convulsions. There were no changes in levels of endocannabinoids or CB(1)-R expression by either seizure activity or type of diet. The level of oleoylethanolamide as well as the sum of N-acylethanolamines were significantly decreased by the KD, but were unaffected by seizure activity. The study shows that the KD had clear antiepileptogenic properties in the pentylenetetrazole kindling model and does not support a role of endocannabinoids in this model. The significance of the decreased hippocampal level of oleoylethanolamide awaits further studies.
KW - Former Faculty of Pharmaceutical Sciences
U2 - 10.1016/j.neuint.2008.10.012
DO - 10.1016/j.neuint.2008.10.012
M3 - Journal article
C2 - 19100800
VL - 54
SP - 199
EP - 204
JO - Neurochemistry International
JF - Neurochemistry International
SN - 0197-0186
IS - 3-4
ER -
ID: 14828202